Free Trial

Sagimet Biosciences (SGMT) Competitors

Sagimet Biosciences logo
$9.41 -0.14 (-1.47%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$9.35 -0.06 (-0.64%)
As of 07/18/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SGMT vs. VERV, NAGE, DYN, CDTX, COLL, BGM, PHVS, NRIX, PRAX, and AKBA

Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Verve Therapeutics (VERV), Niagen Bioscience (NAGE), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Collegium Pharmaceutical (COLL), BGM Group (BGM), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Praxis Precision Medicines (PRAX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.

Sagimet Biosciences vs. Its Competitors

Sagimet Biosciences (NASDAQ:SGMT) and Verve Therapeutics (NASDAQ:VERV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

In the previous week, Verve Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 3 mentions for Verve Therapeutics and 1 mentions for Sagimet Biosciences. Verve Therapeutics' average media sentiment score of 0.32 beat Sagimet Biosciences' score of 0.00 indicating that Verve Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sagimet Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Verve Therapeutics
0 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sagimet Biosciences has a beta of 3.35, suggesting that its share price is 235% more volatile than the S&P 500. Comparatively, Verve Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Verve Therapeutics shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 19.9% of Verve Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sagimet Biosciences currently has a consensus price target of $26.60, indicating a potential upside of 182.68%. Verve Therapeutics has a consensus price target of $14.57, indicating a potential upside of 33.56%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Sagimet Biosciences is more favorable than Verve Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Verve Therapeutics
0 Sell rating(s)
6 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Sagimet Biosciences has a net margin of 0.00% compared to Verve Therapeutics' net margin of -303.64%. Sagimet Biosciences' return on equity of -35.21% beat Verve Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sagimet BiosciencesN/A -35.21% -34.09%
Verve Therapeutics -303.64%-35.81%-27.57%

Sagimet Biosciences has higher earnings, but lower revenue than Verve Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sagimet Biosciences$2M144.30-$45.57M-$1.76-5.35
Verve Therapeutics$32.33M30.08-$198.71M-$2.11-5.17

Summary

Sagimet Biosciences beats Verve Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMT vs. The Competition

MetricSagimet BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$288.65M$2.94B$5.54B$9.43B
Dividend YieldN/A2.48%4.00%4.03%
P/E Ratio-5.3519.8828.2619.77
Price / Sales144.30292.06410.8187.35
Price / CashN/A41.8435.8558.18
Price / Book1.857.678.115.65
Net Income-$45.57M-$55.28M$3.25B$257.97M
7 Day Performance-0.63%4.87%1.64%3.75%
1 Month Performance33.66%11.73%7.28%11.53%
1 Year Performance204.53%3.72%33.14%19.22%

Sagimet Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SGMT
Sagimet Biosciences
1.8963 of 5 stars
$9.41
-1.5%
$26.60
+182.7%
+192.2%$288.65M$2M-5.358
VERV
Verve Therapeutics
2.9244 of 5 stars
$11.16
-1.1%
$14.57
+30.6%
+60.0%$1.01B$59.61M-5.29110
NAGE
Niagen Bioscience
1.4826 of 5 stars
$12.44
-2.1%
$19.50
+56.8%
N/A$1.00B$99.60M73.18120
DYN
Dyne Therapeutics
3.8882 of 5 stars
$8.18
-6.6%
$41.13
+402.8%
-78.2%$995.72MN/A-2.28100Analyst Forecast
Insider Trade
High Trading Volume
CDTX
Cidara Therapeutics
3.6546 of 5 stars
$48.30
-1.0%
$57.14
+18.3%
+374.4%$983.59M$1.27M-1.6490High Trading Volume
COLL
Collegium Pharmaceutical
4.4013 of 5 stars
$30.90
+1.8%
$43.75
+41.6%
-2.8%$975.20M$631.45M25.33210Positive News
BGM
BGM Group
N/A$10.00
-0.3%
N/AN/A$975.14M$25.10M0.00298
PHVS
Pharvaris
1.3116 of 5 stars
$18.00
-3.2%
$36.20
+101.1%
+28.7%$972.60MN/A-5.9830
NRIX
Nurix Therapeutics
2.5788 of 5 stars
$12.36
-2.9%
$30.18
+144.1%
-47.0%$970.48M$54.55M-4.41300Analyst Forecast
Analyst Revision
PRAX
Praxis Precision Medicines
2.4927 of 5 stars
$46.68
-1.2%
$92.11
+97.3%
-0.4%$962.64M$8.55M-4.35110News Coverage
Analyst Forecast
Analyst Revision
AKBA
Akebia Therapeutics
3.8072 of 5 stars
$3.63
+0.3%
$6.75
+86.0%
+183.8%$950.74M$160.18M-17.28430

Related Companies and Tools


This page (NASDAQ:SGMT) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners